{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33.8","upperLimit":"95","value":"80.5"},{"groupId":"OG001","lowerLimit":"93","upperLimit":"99.4","value":"96.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"KIR-occupancy is a relative measure of the fraction of cell surface KIR that is occupied by the IPH2101 monoclonal antibody, and hence is unavailable for binding to HLA ligands.","dispersionType":"Full Range","groups":[{"description":"every 4 weeks by intravenous route over 1 hour, for 4 or up to 8 cycles.","id":"OG000","title":"Arm A: IPH2101 0.2mg/Kg"},{"description":"every 4 weeks by intravenous route over 1 hour, for 4 or up to 8 cycles.","id":"OG001","title":"Arm B: IPH2101 2mg/kg"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From the start up to the end of study (15 months)","title":"Biological Activity of IPH2101 on Killer Immunogloblin Like Receptors (KIR) Occupancy at End of Treatment","type":"SECONDARY","unitOfMeasure":"% of occupancy"}